| __timestamp | CRISPR Therapeutics AG | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 94231000 |
| Thursday, January 1, 2015 | 12573000 | 146394000 |
| Friday, January 1, 2016 | 42238000 | 188272000 |
| Sunday, January 1, 2017 | 69800000 | 166707000 |
| Monday, January 1, 2018 | 113773000 | 401843000 |
| Tuesday, January 1, 2019 | 179362000 | 560909000 |
| Wednesday, January 1, 2020 | 266946000 | 722343000 |
| Friday, January 1, 2021 | 438633000 | 771182000 |
| Saturday, January 1, 2022 | 461645000 | 877090000 |
| Sunday, January 1, 2023 | 387332000 | 877387000 |
| Monday, January 1, 2024 | 320653000 |
Unlocking the unknown
In the dynamic world of biotechnology, research and development (R&D) spending is a critical indicator of innovation and future growth. Over the past decade, Sarepta Therapeutics, Inc. and CRISPR Therapeutics AG have emerged as leaders in this arena. From 2014 to 2023, Sarepta consistently outpaced CRISPR in R&D investment, with a peak in 2023 where its spending was nearly double that of CRISPR. This trend underscores Sarepta's aggressive pursuit of cutting-edge therapies, particularly in genetic medicine.
CRISPR, while trailing in absolute spending, has shown a remarkable growth trajectory, increasing its R&D expenses by over 250% from 2014 to 2023. This reflects its commitment to advancing gene-editing technologies. As these companies continue to innovate, their R&D investments will likely shape the future of medicine, offering hope for groundbreaking treatments and cures.
R&D Insights: How Amgen Inc. and CRISPR Therapeutics AG Allocate Funds
Comparing Innovation Spending: Sanofi and Sarepta Therapeutics, Inc.
Comparing Innovation Spending: Sanofi and CRISPR Therapeutics AG
R&D Insights: How Zoetis Inc. and Sarepta Therapeutics, Inc. Allocate Funds
GSK plc or CRISPR Therapeutics AG: Who Invests More in Innovation?
Research and Development Investment: Bio-Techne Corporation vs CRISPR Therapeutics AG
R&D Spending Showdown: Sarepta Therapeutics, Inc. vs Axsome Therapeutics, Inc.
Sarepta Therapeutics, Inc. vs Ultragenyx Pharmaceutical Inc.: Strategic Focus on R&D Spending
Analyzing R&D Budgets: Sarepta Therapeutics, Inc. vs CymaBay Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Sarepta Therapeutics, Inc. and CRISPR Therapeutics AG
R&D Spending Showdown: Corcept Therapeutics Incorporated vs CRISPR Therapeutics AG
R&D Insights: How CRISPR Therapeutics AG and Soleno Therapeutics, Inc. Allocate Funds